Literature DB >> 23271777

Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?

Mack Roach1, Kimberly Thomas.   

Abstract

Prostate cancer and its management have been intensely debated for years. Recommendations range from ardent support for active screening and immediate treatment to resolute avoidance of screening and active surveillance. There is a growing body of level I evidence establishing a clear survival advantage for treatment of subsets of patients with clinically localized prostate cancer. This chapter presents a review of these randomized controlled trials. We argue that an understanding of this literature is relevant not only to those considering active surveillance but also to those evaluating the merits of screening. In addition, a number of important evidence-based conclusions concerning what should and should not be done can be gleaned from these trials.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271777      PMCID: PMC3540886          DOI: 10.1093/jncimonographs/lgs039

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  68 in total

1.  Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06.

Authors:  S O Asbell; J M Krall; M V Pilepich; H Baerwald; W T Sause; G E Hanks; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-12       Impact factor: 7.038

2.  The number needed to treat: a clinically useful measure of treatment effect.

Authors:  R J Cook; D L Sackett
Journal:  BMJ       Date:  1995-02-18

3.  Radical surgery versus radiotherapy for adenocarcinoma of the prostate.

Authors:  D F Paulson; G H Lin; W Hinshaw; S Stephani
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

4.  Fast neutron radiotherapy for locally advanced prostate cancer: results of an RTOG randomized study.

Authors:  G E Laramore; J M Krall; F J Thomas; T W Griffin; M H Maor; F R Hendrickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-09       Impact factor: 7.038

5.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Authors:  Anthony V D'Amico; Judith Manola; Marian Loffredo; Andrew A Renshaw; Alyssa DellaCroce; Philip W Kantoff
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

6.  Photon versus fast neutron external beam radiotherapy in the treatment of locally advanced prostate cancer: results of a randomized prospective trial.

Authors:  K J Russell; R J Caplan; G E Laramore; C M Burnison; M H Maor; M E Taylor; S Zink; L W Davis; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-01-01       Impact factor: 7.038

7.  Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06.

Authors:  M V Pilepich; J M Krall; W T Sause; R J Johnson; H H Russ; G E Hanks; C A Perez; M Zinninger; K L Martz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-03       Impact factor: 7.038

8.  125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.

Authors:  Kent Wallner; Gregory Merrick; Lawrence True; Steven Sutlief; William Cavanagh; Wayne Butler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-12-01       Impact factor: 7.038

9.  Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer.

Authors:  G J Fellows; P B Clark; L L Beynon; J Boreham; C Keen; M C Parkinson; R Peto; J N Webb
Journal:  Br J Urol       Date:  1992-09

10.  Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.

Authors:  W U Shipley; L J Verhey; J E Munzenrider; H D Suit; M M Urie; P L McManus; R H Young; J W Shipley; A L Zietman; P J Biggs
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-04-30       Impact factor: 7.038

View more
  7 in total

1.  Prostate cancer: impact of national guidelines on brachytherapy monotherapy.

Authors:  Julian Johnson; Mack Roach
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

2.  Prostate cancer: Combining endocrine treatment and radiotherapy: a bright future.

Authors:  Mack Roach
Journal:  Nat Rev Urol       Date:  2016-06-01       Impact factor: 14.432

3.  Effect of rTsP53 on the M1/M2 activation of bone-marrow derived macrophage in vitro.

Authors:  Zhibin Chen; Fan Li; Wen Yang; Yanbing Liang; Hao Tang; Zhenyu Li; Jingguo Wu; Huaping Liang; Zhongfu Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.

Authors:  Christopher J Magnani; Kevin Li; Tina Seto; Kathryn M McDonald; Douglas W Blayney; James D Brooks; Tina Hernandez-Boussard
Journal:  J Natl Compr Canc Netw       Date:  2019-07-01       Impact factor: 11.908

5.  Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.

Authors:  Michael T Schweizer; Peng Huang; Michael W Kattan; Adam S Kibel; Ronald de Wit; Cora N Sternberg; Jonathan I Epstein; Mario A Eisenberger
Journal:  Cancer       Date:  2013-08-13       Impact factor: 6.860

Review 6.  Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Emile N van Lin; Joep G H van Roermund; Philippe Lambin
Journal:  Biomed Res Int       Date:  2016-12-28       Impact factor: 3.411

7.  Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.

Authors:  Christopher J Magnani; Nicolas Bievre; Laurence C Baker; James D Brooks; Douglas W Blayney; Tina Hernandez-Boussard
Journal:  Eur Urol Open Sci       Date:  2020-12-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.